论文部分内容阅读
目的探讨血清中游离前列腺特异抗原(fPSA)、总前列腺特异抗原(tPSA)及其比值对前列腺癌(Pca)的诊断价值。方法采用美国BECKMANCOUNTER全自动微粒子化学发光免疫分析仪定量测定经临床确认的Pca、前列腺增生(BPH)、正常人血清中的fPSAt、PSA并计算其比值。结果Pca、BPH患者PSA水平与正常人比较有非常显著性差异(P均<0.01);Pca患者PSA水平与BPH患者比较无显著性差异(P>0.05),而fPSA 2组比较有显著性差异(P<0.01)。结论fPSA与tPSA联合检测并计算比值可提高Pca的检出率。
Objective To investigate the diagnostic value of serum free prostate specific antigen (fPSA), total prostate specific antigen (tPSA) and its ratio in the diagnosis of prostate cancer (Pca). Methods BECKMAN COUNTER automatic particle chemiluminescence immunoassay analyzer was used to quantitatively determine the clinically confirmed Pca, benign prostatic hyperplasia (BPH), normal human serum fPSAt, PSA and calculate the ratio. Results PSA levels in Pca and BPH patients were significantly different from those in normal controls (all P <0.01). There was no significant difference in PSA levels between Pca and BPH patients (P> 0.05), but there was significant difference between PSA and PPS groups (P <0.01). Conclusion The combined detection of fPSA and tPSA and the calculation of the ratio can improve the detection rate of Pca.